Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/II Study of STSA-1301 Subcutaneous Injection in Healthy Volunteers and ITP Patients
CTR20251285Phase 2Active
- Sponsor
- Staidson Biopharmaceutical
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of STSA-1301 in immune thrombocytopenia (ITP), sponsored by Staidson Biopharmaceutical. Started May 2025; status: active.
02
Drugs
STSA-1301
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20251285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251285.